Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 17.78 USD -0.06%
Market Cap: 1.1B USD
Have any thoughts about
Innoviva Inc?
Write Note

Innoviva Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Innoviva Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Innoviva Inc
NASDAQ:INVA
Accrued Liabilities
$20.8m
CAGR 3-Years
91%
CAGR 5-Years
45%
CAGR 10-Years
-2%
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$33.5B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$13.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$2.6B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$15.7B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$14.1B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
18%
No Stocks Found

Innoviva Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

In the heart of Silicon Valley, Innoviva Inc. has carved out a niche within the pharmaceutical landscape, balancing the art of innovation with the demands of modern healthcare economics. Initially emerging as a dynamic player in drug development, Innoviva made a strategic pivot to focus on the monetization and management of its royalties and collaborations. The company's primary revenue stream flows from partnerships with GlaxoSmithKline (GSK), stemming from co-developed respiratory treatments like the inhaled medications Trelegy and Anoro Ellipta. These partnerships provide Innoviva with steady royalty income based on product sales, allowing it to operate with a lean but effective business model, focusing on maximizing value from its existing assets rather than pursuing the expensive and risky path of drug discovery and development. Beyond merely basking in the comfort of predictable cash flows, Innoviva has tactically reinvested its earnings to fuel further growth and diversification. The company has been channeling resources into acquiring new assets and entering joint ventures that align with its core expertise and long-term vision. This approach not only broadens its portfolio but also hedges against the inherent risks associated with dependency on a limited number of revenue sources. By leveraging its financial strength and strategic partnerships, Innoviva has positioned itself as a nimble player in the pharmaceutical sector, adept at extracting maximum value through prudent financial management and strategic foresight.

INVA Intrinsic Value
22.34 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Innoviva Inc's Accrued Liabilities?
Accrued Liabilities
20.8m USD

Based on the financial report for Sep 30, 2024, Innoviva Inc's Accrued Liabilities amounts to 20.8m USD.

What is Innoviva Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-2%

Over the last year, the Accrued Liabilities growth was -32%. The average annual Accrued Liabilities growth rates for Innoviva Inc have been 91% over the past three years , 45% over the past five years , and -2% over the past ten years .

Back to Top